Clinical Evidence
Most pet supplements never appear in a clinical study at all. PCQ Pet was developed alongside peer-reviewed research published in BMC Veterinary Research, and tested as a full formulation in family-owned dogs over an 8-week course.
The PEA + quercetin precursor formulation behind PCQ was published in BMC Veterinary Research, evaluated against two pain and inflammation models. The follow-up work extended the formula to family-owned dogs with veterinarian-diagnosed joint conditions.
PCQ Pet's specific 5:2:1 ratio is patented under US Patent #11,523,998 for the synergistic effect that emerged from the published in-vitro work.
Why clinical proof matters
Randomized clinical evaluation gives a supplement claim its weight. It is the difference between a marketing tagline and a measured outcome. Clinical work helps:
- Set a baseline before any intervention
- Validate the active formulation, not a single isolated ingredient
- Capture how a real dog changes at home, not in a lab
- Build a defensible profile of tolerability
By testing the full PCQ formulation in family-owned dogs, the entire product, not a single ingredient in isolation, is the thing that gets validated.
The 8-week study
The 8-week study followed family-owned dogs with veterinarian-diagnosed joint conditions. Each dog received daily PCQ for the full window. Outcomes were assessed at baseline and at the 8-week follow-up using force-plate gait analysis and the validated Canine Brief Pain Inventory.
86%
Response rate
86% of dogs showed measurable improvement in pain, physical activity, or quality of life by the end of the 8-week window.
58%
Daily comfort
Average daily comfort scores improved by 58%, capturing how the dog moves and behaves through the day.
57%
Quality of life
Owners reported a 57% improvement in quality of life, including play drive, mood, and engagement with the household.
32%
Pain severity
Average pain severity scores dropped by 32% over the course of the 8-week study.